Study Confirms Excellent Prognosis for Stage I Seminoma

Share this content:

the Cancer Therapy Advisor take:

Patients presenting with stage I seminoma who received a single cycle of adjuvant carboplatin following inguinal orchidectomy have an excellent prognosis, a new study published online ahead of print in the journal Annals of Oncology has shown.

For the retrospective analysis, researchers identified 517 patients with stage I testicular seminomatous germ cell tumor who received one cycle of adjuvant carboplatin South Central England between 1996 and 2013.

Results showed that with a median follow-up of 47.2 months, the 5-year estimated relapse-free survival was 95.0% (95% CI: 92.8, 97.3). In the 21 patients that relapsed, the median time to relapse was 22.7 months. Only four patients experienced a relapse beyond 3 years and 95% of relapsed patients had retroperitoneal lymph node metastases.

Researchers found that 76% of those that relapsed had elevated tumor markers at the time of relapse. Nearly 4% of all patients developed a new contralateral testicular germ cell cancer.

The findings suggest that increasing tumor size is associated with an increased risk of post-chemotherapy relapse.

For high-risk, localized prostate cancer, adjuvant chemotherapy improved the overall survival from 8
Patients presenting with stage I seminoma who received adjuvant carboplatin following inguinal orchidectomy have excellent prognosis.
Following inguinal orchidectomy, management options for patients with stage I seminoma include initial surveillance or treatment with adjuvant radiotherapy or chemotherapy. The anticipated relapse rate for patients followed by surveillance alone is approximately 15%, with adjuvant treatment this risk is reduced to approximately 4-5% at five years.
READ FULL ARTICLE From Annals of Oncology

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs